Synonyms: CC-220 | compound 6 [PMID: 28425720]
Compound class:
Synthetic organic
Comment: Iberdomide (CC-220) is a novel cereblon modulator [3], functionally akin to lenalidomide and pomalidomide.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
CC-220 is being evaluated in clinical trials for systemic lupus erythematosus (SLE; Phase 2), and for relapsed and refractory multiple myeloma (alone or in combination with dexamethasone (Phase 1/2). |
Mechanism Of Action and Pharmacodynamic Effects |
CC-220 binding to cereblon promotes CRL4-CRBN E3 ligase-mediated degradation of the DNA-binding proteins Ikaros (IKZF1) and Aiolos (IKZF3), which are two cereblon substrates [3]. The downstream effects of degrading these proteins mediate the antiproliferative and immunomodulatory activities of cereblon-binding drugs [1]. Polymorphisms of the IKZF3 gene have been associated with systemic lupus erythematosus in a Chinese Han population [2]. |